Effect of suppressive acyclovir administered to HSV-2 positive mothers from week 28 to 36 weeks of pregnancy on adverse obstetric outcomes: a double-blind randomised placebo-controlled trial

Table 3 Side effects per study arm for HSV-2 positive pregnant participants in Mulago Hospital between January 2014 and February 2015

Characteristic	Acyclovir N =100(%)	Placebo N =100(%)	P values
Total
Nausea and vomiting
None	93 (93.0)	96 (96.0)
Yes	7 (7.0)	4 (4.0)	0.352
Hb level^a
Normal	72 (78.3)	74(77.1)
Abnormal Less than 11.9 g/dl	20 (21.7)	21 (22.9)	0.846
Creatinine level^a
Normal	91 (98.9)	90 (94.7)
abnormal	1 (1.1)	5 (5.3)	0.105
Alanine transferase (ALT)^a
Normal	89 (96.7)	94 (98.9)
abnormal	3 (3.3)	1 (1.1)	0.297

We were able to assess history of nausea and vomiting for all the study participants. Thirteen participants declined the second blood draw, thus we only assessed blood counts, renal functions tests and liver function tests for 92 and 95 participants in the acyclovir and placebo arms respectively. There were no differences in adverse drug reactions between the acyclovir and placebo arms
^aHere the numbers are not adding up to 100 due to some participants declining closing laboratory tests blood draws; 92 in the acyclovir arm and 95 in the placebo arm

ISSN: 1742-4755